Table 3 Summary of effects of each mutation on EEEV HS or receptor interactions
WT | 71–77 | 84–119 | 156–157 | |
|---|---|---|---|---|
SINV/EEEV CHO-pgsA-745 infectivity relative to CHO-K1 infectivity | 6.4 ± 1.1% | 122.8 ± 12.7% | 8.2 ± 2.5% | 85.4 ± 21.7% |
SINV/EEEV heparinase II infection sensitivity | +++ | − | +++ | +++ |
SINV/EEEV heparin binding affinity (KD apparent) | 3.5 ± 0.8 nM | 132.8 ± 57.6 nM | 5.1 ± 0.6 nM | 163.3 ± 200.6 nM |
SINV/EEEV susceptibility of infection to increased NaCl | +++ | − | ++ | ++ |
EEEV Genome:BHK PFU (Fold-Change to WT) | 1 | 89.5 | 1.8 | 298.1 |
SINV/EEEV K562-VLDLR infectivity/VLDLR LA(1-2)-Fc neutralization | +++/+++ | +/+ | ++/+++ | +/− |
SINV/EEEV VLDLR LA(1-2)-Fc binding affinity (KD apparent) | 4.3 ± 1.4 nM | 1.1 ± 0.4 nM | 5.9 ± 1.4 nM | ND |
Mouse AST sc. infection with EEEVs | 4.1 ± 0.5 | 5.2 ± 0.5 | 3.7 ± 0.2 | 6.2 ± 0.7 |
Mouse mortality ic. infection with SINV/EEEV chimeras | 60% | 0% | 20% | 0% |
VLDLR LA(1-2)-Fc in vivo protection from infection with EEEVs | +++ | ++ | ++ | − |
Mosquito midgut EEEV infectivity | +++ | + | ++ | − |
